Lantern Pharma’s AI platform RADR identified 82 new antibody-drug conjugate targets, 290 cancer-specific pairings, and 729 effective payloads from 50,000+ compounds. A PLOS One study validates the findings. CEO Panna Sharma says the approach can cut ADC development time 30-50% and costs up to 60%.
